Hepatitis B News and Research

Latest Hepatitis B News and Research

CSL to distribute Cerus' INTERCEPT Blood System in Australia, New Zealand

Cerus Corporation announced today that it has entered into an agreement with CSL Limited, Biotherapies division to distribute Cerus' INTERCEPT Blood System for platelets in Australia and New Zealand. The INTERCEPT Blood System is designed to provide increased protection from a broad range of transfusion-transmitted pathogens, including bacteria and emerging pathogens such as the dengue and chikungunya viruses.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

'Achilles heel' for HCV infection

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have found that an enzyme associated with the storage of fat in the liver is required for the infectious activity of the hepatitis C virus (HCV). This discovery may offer a new strategy for treating the infection.

11 Oct 2010

Teen sex on the rise and so are STIs: Survey

A survey of 8,800 Australian year 10 and year 12 students in 300 schools around Australia was taken in three snapshots between 1997 and 2008. It was found that with the rise of risky alcohol consumption among Australia's teenagers there is also a surge of sex “under the influence” and number of sexual partners and unsafe and unprotected intercourse. However, the awareness of HIV/AIDS remained high.

6 Oct 2010

RDI launches HIV-TRePS system to predict patients’ response to HIV drugs

A ground-breaking system for predicting how individual patients with HIV and AIDS will respond to different drugs is launched today by RDI, a UK-based not-for-profit research group. The experimental system, called the HIV Treatment Response Prediction System (HIV-TRePS), is available free of charge over the Internet and helps physicians select the best treatment for their patients.

6 Oct 2010

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Johnson & Johnson and Crucell N.V. today announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion in a recommended cash tender offer.

6 Oct 2010

Mass. hospital sale talks seeking to protect employee retirement plans; Conn. Gov. ask for waiver in preexisting insurance plan

Representatives of Caritas Christi Health Care, the private equity firm seeking to buy it, and the attorney general's office are working on a tentative agreement to protect the retirement plans of 13,000 employees and keep the chain's hospitals open for at least five years.

6 Oct 2010

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

Altravax, Inc. announced today that it has been awarded two SBIR grants totaling $1.2 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1.

6 Oct 2010

New approach method could simplify study and treatment of human diseases

Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as foreign and rejects them.

6 Oct 2010

NSSHB study provides update on contemporary Americans' sexual behaviors

Findings from the largest nationally representative study of sexual and sexual-health behaviors ever fielded, conducted by Indiana University sexual health researchers, provides an updated and much needed snapshot of contemporary Americans' sexual behaviors, including a description of more than 40 combinations of sexual acts that people perform during sexual events, patterns of condom use by adolescents and adults, and the percentage of Americans participating in same-sex encounters.

5 Oct 2010

cobas TaqScreen DPX Test now available with CE Mark: Roche

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay.

5 Oct 2010

HGS receives Complete Response Letter from FDA for ZALBIN drug

Human Genome Sciences, Inc. today announced that, as expected, it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for 900-mcg ZALBIN (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C.

5 Oct 2010

FDA provides Celsion guidance for Thermodox NDA to treat primary liver cancer

Celsion Corporation, a leading oncology drug development company, announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) that the requirements for non-clinical studies have been met for the New Drug Application (NDA) of ThermoDox.

4 Oct 2010

Thomas Jefferson University Hospital commences live donor liver transplant program

The Division of Transplantation in the Department of Surgery at Thomas Jefferson University Hospital (TJUH) has started a live donor liver transplant program. Live donor liver transplantation (LDLT) is a procedure in which a living person donates a portion of his or her liver to another person. Combined, the two operations typically take about 12 hours. Since the program began in summer 2010, three patients and their donors have successfully undergone the procedure.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Benitec Limited, a leading Australian based company specialising in RNA interference (RNAi) technology is pleased to announce the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

4 Oct 2010

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

New data on multiple Bristol-Myers Squibb Company compounds will be presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 29 to November 2.

3 Oct 2010

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.

1 Oct 2010

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.

1 Oct 2010

Hepatitis B News and Research

Latest Hepatitis B News and Research

CSL to distribute Cerus' INTERCEPT Blood System in Australia, New Zealand

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

'Achilles heel' for HCV infection

Teen sex on the rise and so are STIs: Survey

RDI launches HIV-TRePS system to predict patients’ response to HIV drugs

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Mass. hospital sale talks seeking to protect employee retirement plans; Conn. Gov. ask for waiver in preexisting insurance plan

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

New approach method could simplify study and treatment of human diseases

NSSHB study provides update on contemporary Americans' sexual behaviors

cobas TaqScreen DPX Test now available with CE Mark: Roche

HGS receives Complete Response Letter from FDA for ZALBIN drug

FDA provides Celsion guidance for Thermodox NDA to treat primary liver cancer

Thomas Jefferson University Hospital commences live donor liver transplant program

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

Achillion initiates ACH-1625 Phase II dosing for HCV infection

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis B News and Research

Latest Hepatitis B News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in